Panbela Therapeutics (PBLA) Competitors $0.37 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends PBLA vs. JAGX, BCDA, BFRI, IMCC, HOTH, LIXT, NCNA, XCUR, ONCT, and PPBTShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Jaguar Health (JAGX), BioCardia (BCDA), Biofrontera (BFRI), IM Cannabis (IMCC), Hoth Therapeutics (HOTH), Lixte Biotechnology (LIXT), NuCana (NCNA), Exicure (XCUR), Oncternal Therapeutics (ONCT), and Purple Biotech (PPBT). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Jaguar Health BioCardia Biofrontera IM Cannabis Hoth Therapeutics Lixte Biotechnology NuCana Exicure Oncternal Therapeutics Purple Biotech Panbela Therapeutics (NASDAQ:PBLA) and Jaguar Health (NASDAQ:JAGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk. Does the media favor PBLA or JAGX? In the previous week, Jaguar Health's average media sentiment score of 1.11 beat Panbela Therapeutics' score of 0.00 indicating that Jaguar Health is being referred to more favorably in the news media. Company Overall Sentiment Panbela Therapeutics Neutral Jaguar Health Positive Do analysts recommend PBLA or JAGX? Panbela Therapeutics currently has a consensus target price of $500.00, suggesting a potential upside of 135,035.14%. Given Panbela Therapeutics' higher probable upside, equities research analysts clearly believe Panbela Therapeutics is more favorable than Jaguar Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Panbela Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Jaguar Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Is PBLA or JAGX more profitable? Panbela Therapeutics has a net margin of 0.00% compared to Jaguar Health's net margin of -350.18%. Panbela Therapeutics' return on equity of 0.00% beat Jaguar Health's return on equity.Company Net Margins Return on Equity Return on Assets Panbela TherapeuticsN/A N/A -269.84% Jaguar Health -350.18%-412.63%-67.24% Which has more risk and volatility, PBLA or JAGX? Panbela Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Jaguar Health has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Which has preferable earnings & valuation, PBLA or JAGX? Panbela Therapeutics has higher earnings, but lower revenue than Jaguar Health. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPanbela TherapeuticsN/AN/A-$25.26M-$123.450.00Jaguar Health$10.19M0.96-$41.30MN/AN/A Does the MarketBeat Community prefer PBLA or JAGX? Jaguar Health received 1817 more outperform votes than Panbela Therapeutics when rated by MarketBeat users. Likewise, 88.73% of users gave Jaguar Health an outperform vote while only 62.07% of users gave Panbela Therapeutics an outperform vote. CompanyUnderperformOutperformPanbela TherapeuticsOutperform Votes1862.07% Underperform Votes1137.93% Jaguar HealthOutperform Votes183588.73% Underperform Votes23311.27% Do institutionals & insiders hold more shares of PBLA or JAGX? 4.4% of Panbela Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Jaguar Health shares are owned by institutional investors. 0.0% of Panbela Therapeutics shares are owned by insiders. Comparatively, 0.0% of Jaguar Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryPanbela Therapeutics and Jaguar Health tied by winning 6 of the 12 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29M$7.02B$5.40B$8.53BDividend YieldN/A7.97%5.15%4.14%P/E Ratio0.009.53113.7615.14Price / SalesN/A385.111,483.0493.53Price / CashN/A47.3339.7134.04Price / Book-0.025.324.665.01Net Income-$25.26M$153.56M$119.06M$225.46M7 Day Performance5.71%0.12%0.79%0.37%1 Month Performance-3.90%15.23%5.65%3.57%1 Year Performance-98.05%41.16%36.80%29.42% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela Therapeutics0.9838 of 5 stars$0.37flat$500.00+135,035.1%-97.6%$1.29MN/A0.007JAGXJaguar Health1.018 of 5 stars$1.06-1.9%N/A-95.0%$5.20M$10.19M0.0050Gap UpBCDABioCardia2.6002 of 5 stars$2.37-2.1%$25.00+954.9%-57.9%$5.03M$428,000.00-0.4416News CoverageBFRIBiofrontera2.2395 of 5 stars$0.93+6.9%$7.00+649.5%-76.9%$4.86M$35.24M-0.1670News CoverageGap DownHigh Trading VolumeIMCCIM Cannabis0.3972 of 5 stars$2.17flatN/A-29.1%$4.84M$49.88M-0.57340Positive NewsGap UpHOTHHoth Therapeutics3.3034 of 5 stars$0.90-7.2%$3.50+287.9%-27.1%$4.84MN/A-0.564Gap UpLIXTLixte Biotechnology0.5884 of 5 stars$2.13+2.4%N/A-25.5%$4.79MN/A-1.203Positive NewsHigh Trading VolumeNCNANuCana3.0979 of 5 stars$1.73-1.1%$25.00+1,345.1%-86.9%$4.57MN/A-0.1430Positive NewsXCURExicure1.7367 of 5 stars$2.62+1.6%N/A+409.7%$4.53M$500,000.00-0.5850ONCTOncternal Therapeutics2.479 of 5 stars$1.50-2.0%$20.00+1,233.3%-76.2%$4.44M$790,000.00-0.1230PPBTPurple Biotech2.1285 of 5 stars$3.30-5.2%$200.00+5,960.6%N/A$4.39MN/A-0.2520News CoverageHigh Trading Volume Related Companies and Tools Related Companies Jaguar Health Competitors BioCardia Competitors Biofrontera Competitors IM Cannabis Competitors Hoth Therapeutics Competitors Lixte Biotechnology Competitors NuCana Competitors Exicure Competitors Oncternal Therapeutics Competitors Purple Biotech Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PBLA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
